Kornimate/medical-research-clean huggingface dataset:
myhand: an active hand orthosis for stroke patients

Conditions: Stroke

Summary: this study seeks to explore the efficacy of several control mechanisms for the device and the impact of a device training program on its utility as a neuroprosthetic and training tool for upper limb recovery.

hand rehabilitation through occupational therapy is critical for many stroke survivors, but it is also greatly limited by insurance coverage, shortage of therapists, and logistic constraints. to address this, stroke patients need a rehabilitation method they can use on their own, without direct clinical supervision, and for activities of daily living. myhand is a wearable and active hand orthosis consisting of a glove and forearm splint, equipped with actuators and tendons which connect to the fingers.

Eligibility criteria:
inclusion criteria: * subjects over 18 years of age * history of stroke resulting in significant upper limb impairment * full passive range of motion * gross control of the proximal upper extremity * lacks timely grasp/release * no more than moderate flexor tone * intact cognition exclusion criteria include: * other neurological/orthopedic disorders * excessive spasticity/contracture

Keywords: hand orthosis stroke
sonography in an unselected population of acute admitted patients with respiratory symptoms

Conditions: Dyspnoea; Chest Pain; Cough

Summary: the purpose of this study is to determine whether focused sonography of the heart, lungs and deep veins can increase the number of patients with respiratory symptoms correctly diagnosed in an emergency department.


Eligibility criteria:
inclusion criteria: all 4 of the following must be present: 1. the sonographic examination can be performed before or within 1 hour after the primary evaluation 2. patient is 18 years or older 3. patient able and willing to give informed consent 4. one ore more of the following symptoms or clinical findings at admission to the emergency department * respiratory rate \> 20 breaths per minute * saturation \< 95% * oxygen therapy initiated * the patient has a principal complaint of dyspnoea * the patient has a principal complaint of coughing * the patient has a principal complaint of chest pain exclusion criteria: one of the following: 1. the sonographic examination can not be performed within 1 hour after the primary evaluation 2. the patient is 17 years or younger 3. the patient not able or willing to give informed consent
liquid biopsy in mature b-cell tumors

Conditions: Mature B-Cell Neoplasm

Summary: the study aims at assessing whether cell free dna genotyping can improve the accuracy of early prediction of cure in mature b-cell tumor patients and whether it represents an accessible source of tumor dna for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.

clinical data and peripheral blood samples (20 ml in edta tubes and 20 ml in cell-free dna bct tubes) will be collected during the clinico/laboratory visits that are planned as per clinical routine at the time of mature b-cell tumor diagnosis, before treatment, at the time of interim pet/ct, at the time of end of treatment pet/ct and at the time of disease relapse. clinical variables, international prognostic index, results of plasma cell free dna genotyping and of pet-ct will be analyzed descriptively. the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the compiled results of plasma cell free dna genotyping and interim pet-ct (for chl and dlbcl), or plasma cell free dna genotyping and baseline international prognostic index (for fl and mcl) in identifying patients that are progression free for \>24 months after first line therapy will be calculated and compared with those obtained by the sole interim pet-ct (chl and dlbcl) or the sole international prognostic index (fl, mcl).

Eligibility criteria:
inclusion criteria: * male or female adults 18 years or older * documented diagnosis of mature b-cell tumor according to who 2008 criteria * willing and able to comply with scheduled study procedures * evidence of a signed informed consent

Keywords: liquid biopsy classical hodgkin lymphoma diffuse large b cell lymphoma follicular lymphoma mantle cell lymphoma mutations
paclitaxel coated pta balloons for treatment of dysfunctional av fistulae and grafts

Conditions: Dysfunctional AV Graft; Dysfunctional AV Fistula

Summary: the purpose of this study is to evaluate the lutonix® 035 drug coated balloon pta catheter (ce mark) for use as intended in the treatment of subjects with clinically significant hemodialysis vascular access stenosis or occlusion.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. the subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the informed consent form (icf) 3. hemodialysis access on the arm presenting with any clinical abnormalities as defined in the k/doqi guidelines 4. native av fistula or synthetic av graft has been implanted ≥30 days 5. target de novo or non-stented restenotic lesion(s) consisting of a \>50% stenosis by visual estimate. successful treatment of non target lesion(s) (residual stenosis \<30% by visual estimate) without procedural complication by standard of care 6. successful predilatation of the target lesion with a percutaneous transluminal angioplasty (pta) balloon 7. intended target lesion(s) (maximum of 2) can be treated 8. no other prior surgical or vascular interventions within 2 weeks before and/or planned 30 days after the treatment exclusion criteria: 1. women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children 2. known contraindication (including allergic reaction) or sensitivity to contrast media, asa, clopidogrel, ticlopidine, paclitaxel (mild to severe cases), that cannot be adequately managed with pre-and post-procedure medication 3. life expectancy \<12months 4. scheduled for kidney transplant or peritoneal dialysis in the next 12months; 5. thrombosed access 6. stent in the target treatment area 7. blood coagulative disorder, sepsis, or current av access infection 8. currently participating in an investigational drug, biologic, or device study, or previous enrollment in this study note: enrollment in another investigational drug, biologic, or device study during the follow- up period is not allowed
neoadjuvant of axitinib plus pd-1 to improve disease free survival of patients with renal cell carcinoma

Conditions: Renal Cell Carcinoma; Neoadjuvant

Summary: the study included 246 rcc patients who were at high risk for recurrence after nephrectomy (t2g3-4 or t3-4 or n1). they were randomly divided to receive axitinib plus pd-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus pd-1.

given the good results of tki plus pd-1 in our previous cases and its good effect on advanced rcc, we plan to eliminate tumor micrometastases and improve anti-tumor immunity with the neoadjuvant combination of axitinib plus pd-1, so as to improve patient outcomes. the study included 246 rcc patients who were at high risk for recurrence after nephrectomy (t2g3-4 or t3-4 or n1). they were randomly divided to receive axitinib plus pd-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus pd-1 and provide evidence-based medical evidence for clinical perioperative treatment of these patients.

Eligibility criteria:
inclusion criteria: 1. males or females between 18 years old and 80 years old; 2. histopathologically confirmed clear cell carcinoma; 3. staged as t2g3-4 or t3-t4 or n1 exclusion criteria: 1. with distant metastasis 2. severe liver and renal dysfunction, combined with other serious diseases; 3. serious cardiovascular disease, including any of the following: myocardial infarction or arteritis or venous thrombosis (such as pulmonary embolism) in the past 1 year; 4. severe/unstable angina pectoris; uncontrolled hypertension; 5. class iii or iv heart failure by new york heart association (nyha) functional classification; 6. ventricular arrhythmia requiring drug treatment.
dosimetric comparison of three radiation techniques for hypofractionated whole breast radiotherapy in early breast cancer

Conditions: Breast Cancer

Summary: we aim to compare three different radiation delivery techniques, namely three-dimensional conformal radiation therapy (3d-crt), intensity modulated radiotherapy (imrt) and volumetric modulated radiation therapy (vmat) in left-sided early breast cancer patients.


Eligibility criteria:
inclusion criteria: * left sided early breast cancer patients. should have histopathological prove to have invasive breast cancer. operated by breast conservative surgery. have no associated comorbidities exclusion criteria: * locally advanced breast cancer. patients who have total mastectomy. patients who had previous chest irradiation or known comorbidities.

Keywords: computer assisted, radiotherapy
survey in post-menopausal women followed up after treatment with anastrozole as adjuvant therapy

Conditions: Breast Cancer

Summary: the purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.


Eligibility criteria:
inclusion criteria: * woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors

Keywords: breast cancer anastrozole
application of a simplified method of complete denture fabrication for severely resorbed mandibular ridges

Conditions: Edentulous Mouth; Edentulous Jaw

Summary: background: the literature has shown that simplified methods for complete denture fabrication can be as effective as the traditional techniques, but with less expenditure of time and resources, without prejudice to the patients. however, the effectiveness of these simplified methods for patients with more complex medical conditions haven't been deeply explored. objectives: to evaluate the effectiveness of a proposed simplified method for complete dentures fabrication for patients with severely resorbed mandibular alveolar bones. method: edentulous patients requesting treatment with bimaxillary complete dentures in a university clinic will be rehabilitated following a simplified technical proposal, being divided randomly into two groups according to the mandibular arch molding technique. in group a, a single impression with alginate through pre-fabricated trays will be performed, while patients allocated in group b will receive a second molding with a more complex technique. after 3 and 6 months, besides important clinical parameters, it will be investigated aspects related to patient's perceptions about the success of treatment. the study will be conducted with a minimum of 30 participants per group, and comparisons between the two groups will be made by means of tests suitable for distribution of data.


Eligibility criteria:
inclusion criteria: * complete edentulism for at least one year; * desire to receive a pair of new conventional complete dentures * mental receptiveness; * good understanding of spoken portuguese exclusion criteria: * disorders of the masticatory system; * pathological changes of residual ridges; * debilitating systemic diseases.

Keywords: complete denture quality of life patient satisfaction
thoracotomy: intercostal nerve block versus epidural anesthesia

Conditions: Thoracotomy

Summary: postoperative pain and consecutive reduction of pulmonary function after thoracic surgery still is a major clinical problem and challenge in anesthesia. thoracic epidural anesthesia is commonly considered to be the "gold standard" for postoperative pain control and restoration of pulmonary function after thoracic surgery. thus, the aim of the present study is to investigate whether an intercostal nerve block with ropivacaine plus intravenous pca with morphine is as effective as thoracic epidural anesthesia with respect to postoperative pain control and pulmonary


Eligibility criteria:
inclusion criteria: * patients undergoing elective pulmonary surgery, including pneumonectomy, bilobectomy, lobectomy, typical and atypical segmentectomy, via a lateral or posterolateral thoracotomy without chest-wall resection exclusion criteria: * age\<18 yr * any contraindication to epidural anaesthesia, intercostal nerve block or the use of ropivacaine, morphine, metamizol or diclofenac * lack of patient's cooperation * any type of chronic painful condition or current opioid use

Keywords: pain thoracotomy pulmonary function epidural anesthesia intercostal nerve block
impact of nmes on spirometry values, functional capacity and quality of life in patients with pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension (ph) features symptoms related to a decreased cardiac autonomic response, pulmonary function and exercise capacity. non-pharmacological interventions are low cost and can significant enhance outcomes in these patients. neuromuscular electrical stimulation (nmes) has been proposed as a viable therapeutic approach in patients with functional limitations, particularly those that present with difficulty to perform exercise protocols. objective: to evaluate the impact of nmes on exercise capacity, spirometry values and quality of life of patients with ph. material and methods: prospective randomized controlled study with a control group (gc, n9) and nmes goup (ge, n8). quality of life and exercise capacity through the six-minute walk test (6mwt) were assessed before and after the nmes protocol. results: the ge presented with a significant improvement in distance walked in the 6mwt, cycle ergometry, spirometry and quality of life in the areas of vitality, emotional and social aspects of the questionnaire short form health survey-36. conclusion: nmes is a useful tool in the treatment of patients with ph, resulting in improved exercise capacity, quality of life and lung function testing.


Eligibility criteria:
inclusion criteria: males and females greater than or equal to 18 years of age, clinically stable with optimized drug therapy in the last 3 months, previously diagnosed with a mean pulmonary arterial pressure ≥ 25 mmhg by right heart catheterization and who agreed to participate by signing an informed consent were included. exclusion criteria: exclusion criteria included a diagnosis of down syndrome, orthopedic disease or neurologic or diagnoses, history of acute heart attack, use of beta-blockers, any urgent or elective surgical intervention during the implementation of the protocol, those who used assistive devices to ambulate or develop an infectious process during the study protocol.

Keywords: pulmonary hypertension peripheral muscle electrostimulation capacity of the exercises quality of life
change of nerve conduction properties in ivig dependent neuropathies

Conditions: Guillain-Barre Syndrome; CIDP; Multifocal Motor Neuropathy

Summary: ivig exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for ivig. in this study the role of ivig on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

ivig exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for ivig. in this study the role of ivig on short term nerve conduction in patients with immune-mediated neuropathies will be explored

Eligibility criteria:
inclusion criteria: * immune neuropathy * age above 18 y * ivig treatment exclusion: * no ivig treatment
acute effects of thai traditional massage on cerebrovascular reactivity in ischemic stroke patients

Conditions: Ischemic Stroke

Summary: the investigators hypothesize that acute thai traditional massage will yield beneficial effects on cerebrovascular reactivity in ischemic stroke patients.


Eligibility criteria:
inclusion criteria: 1. a single ischemic stroke with middle cerebral artery (mca) stenosis 2. men or women age 50-80 years 3. physician's approvals to participate the study 4. stroke experienced at least 7 days of ischemic stroke onset and no more than 6 months before study enrollment 5. the modified rankin scale level is 2 or 3 exclusion criteria: 1. history of serious diseases * musculoskeletal diseases (chronic arthritis, lower spondylosis/spondylolisthesis with radiculopathy, spinal deformity, cervical spondylosis, rheumatoid arthritis) * cardiovascular diseases (poorly control hypertension, heart disease class c and d) * neurological disorders (peripheral neuropathy, parkinson) * respiratory diseases (chronic obstructive pulmonary disease) * brain disorders (cardioembolic, severe dementia, alzheimer's disease) * medical condition precluding taking anticoagulant and statin drug 2. temporal window were not found

Keywords: ischemic stroke thai traditional massage vascular function cerebral blood flow cerebrovascular reactivity
a study of bevacizumab combined with fluzoparib/chemotherapy or fluzoparib in the treatment of ovarian cancer

Conditions: Ovarian Cancer

Summary: this study was designed to explore the safety and efficacy of bevacizumab combined with fluzoparib, bevacizumab combined with chemotherapy or fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.

this purpose of this study is to explore efficacy of bevacizumab combined with fluzoparib, bevacizumab combined with chemotherapy or fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.besides the efficacy,we focus on the safety and quality of life in the new treatments.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years, female; 2. recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer proven to be platinum-resistant by histology or cytology; 3. ecog score was 0-1; 4. expected survival time \> 12 weeks; 5. normal or abnormal bone marrow, kidney, and liver function of the patient has no clinical significance, and the specific situation will be comprehensively determined by the investigator; 6. patients not previously treated with parpi or targeted drugs; 7. the patient has taken effective contraceptive measures within 14 days prior to screening and is willing to sign the notification until the last medication no pregnancy plan and voluntary use of effective contraceptive measures within the next 6 months; 8. the subject or his/her legal guardian can communicate well with the investigator, understand and comply with the requirements of this study, and understand and sign the informed consent. exclusion criteria: 1. known allergy to fluzopalil or study drug components; 2. patients with any factors affecting oral administration (such as previous gastric or small bowel resection, or current atrophic gastritis, chronic intestinal disease, gastrointestinal bleeding, dysphagia, gastrointestinal obstruction, or diarrhea greater than grade 1, including those who have recovered but have not recovered); 3. patients who underwent major surgery or gastrointestinal surgery affecting drug absorption, open biopsy, severe traumatic injury, wound unhealed or did not recover from major surgery within 1 month before the trial; 4. before the first administration, patients have used strong cyp3a inhibitors (such as itraconazole, telithromycin, clarithromycin, ritonavir, etc.) or medium cyp3a inhibitors (such as ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil, etc.); patients who had used strong cyp3a inducers (e.g., phenobarbide, enzyluamide, phenytoin, rifampicin, rifambutin, rifapentine, carbamazepine, nevirapine and st. john's herb) or medium cyp3a inducers (e.g., bosentan, efavirenz, modafinil, etc.) and did not reach 3 elimination half-lives; 5. pregnant or lactating women or subjects who cannot use contraception as required; 6. those who have special requirements on diet and cannot accept uniform diet; 7. as judged by the researcher, there are other circumstances that are not suitable for the researcher.

Keywords: platinum-resistant recurrent ovarian cancer bevacizumab fluzoparib
cross-sectorial use of patient-reported outcomes in chronic degenerative shoulder conditions

Conditions: Shoulder Disease; Shoulder Impingement; Shoulder Osteoarthritis; Shoulder Frozen; Shoulder Capsulitis; Shoulder Bursitis; Shoulder Impingement Syndrome; Rotator Cuff Syndrome; Rotator Cuff Syndrome of Shoulder and Allied Disorders

Summary: this research project aims to test if systematic (extensive) use of patient-reported outcomes across treatment boundaries can 1. improve patients' and health professionals' understanding of individual patients' conditions and health changes, 2. improve indications for treatment, 3. strengthen patient empowerment, and 4. reduce patients' utilization of health services. the study will be performed in the particular context of patients with chronic degenerative conditions of the shoulder. these patients are characterized by contact with numerous health professionals from different health sectors, such as general practitioner, physiotherapists and surgical referral centres, which challenges coherence and communication for the individual treatment decisions. the research project will be performed as a randomized controlled trial (rct) with a 1-year inclusion period and two years of follow-up.


Eligibility criteria:
inclusion criteria: * shoulder pain with no acute trauma exclusion criteria: * age \<18 years * non-danish citizenship * unable to understand written or spoken danish * inability to master electronic means of communication and/or not having an electronic communication (e-boks) * employee at participating centre or other relation to participating health professionals that might affect independent consent * psychiatric conditions, mental conditions and substance abuse that might affect the ability to provide informed consent or responding to proms * disseminated malignant condition, other serious medical conditions or other life crisis where the focus on a shoulder research project is unreasonable * already included in the study with the contralateral shoulder
reduced radiation dose and ir-impact on coronary calcium quantification

Conditions: Atherosclerotic Plaque

Summary: evaluation of reduced radiation dose iterative reconstruction reconstructions for calcium scoring compared to full dose filtered back projection reconstructions


Eligibility criteria:
inclusion criteria: * patients undergoing routine calcium scoring ct at facilities at the university of pennsylvania exclusion criteria: * patients found to have no coronary calcium on full dose fbp reconstructions
study of undertreatment of patients with dyslipidemia in bulgaria

Conditions: Dyslipidemia

Summary: the purpose of this study is to establish the proportion of bulgarian patients on lipid-lowering pharmacological treatment reaching the ldl-c goals according to the fourth joint european task force guidelines.


Eligibility criteria:
inclusion criteria: * lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks * signed informed consent exclusion criteria: * informed consent not provided

Keywords: dyslipidemia target cholesterol undertreatment